Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
about
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System.Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.The difference between medicine and magic is that magicians know what they are doingENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Peptide receptor radionuclide ...... d randomized, or personalized?
@en
Peptide receptor radionuclide ...... d randomized, or personalized?
@nl
type
label
Peptide receptor radionuclide ...... d randomized, or personalized?
@en
Peptide receptor radionuclide ...... d randomized, or personalized?
@nl
prefLabel
Peptide receptor radionuclide ...... d randomized, or personalized?
@en
Peptide receptor radionuclide ...... d randomized, or personalized?
@nl
P2860
P1476
Peptide receptor radionuclide ...... d randomized, or personalized?
@en
P2093
Michael S Hofman
P2860
P2888
P304
P356
10.1007/S00259-013-2621-6
P577
2013-11-13T00:00:00Z